We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Pilots Risk-Benefit Framework in Six NME Applications
FDA Pilots Risk-Benefit Framework in Six NME Applications
December 30, 2011
The FDA is using a decisionmaking matrix to weigh expected clinical benefits for biopharmaceuticals against their risks in a pilot program using six NME applications under review.